AST-487
| Overview | |
| Catalog # | bs-75626c-1mg |
| Product Name | AST-487 |
| Specifications | |
| Storage Buffer | Solid |
| Storage Condition | Stable for 2 years after receipt when stored at -20°C. |
| Target | |
| Product Information | CAS Number: 630124-46-8 Molecular formula: C26H30F3N7O2 Molecular weight: 529.6 Purity: >95% Appearance: White to off-white solid. Solubility: Soluble in DMSO, DMF or ethanol. InChiKey: ODPGGGTTYSGTGO-UHFFFAOYSA-N SMILES: CCN1CCN(CC2=C(C=C(NC(=O)NC3=CC=C(OC4=CC(NC)=NC=N4)C=C3)C=C2)C(F)(F)F)CC1 |
| Description | AST487 is an inhibitor of RET (IC50 = 0.88µM), FLT3 (Ki = 0.52µM), KDR (IC50 = 0.17µM), c-Abl (IC50 = 0.02µM) and c-Kit (IC50 = 0.5µM). AST-487 has been shown to inhibit RET autophosphorylation and activation of downstream effectors and to prevent the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. In xenografts of NIH3T3 cells expressing oncogenic RET and of the MTC cell line TT in nude mice, AST-487 dose dependently inhibited tumor growth. AST-487, which selectively targets mutant FLT3 protein kinase activity, is also shown to override PKC412 resistance in vitro, and has significant antileukemic activity in an in vivo model of FLT3-ITD(+) leukemia. The combination of AST-487 with standard chemotherapeutic agents leads to enhanced inhibition of proliferation of mutant FLT3-expressing cells. AST-487 displays high selectivity and potency toward FLT3 as a molecular target, and could potentially be used to override drug resistance in AML. |